DRUG REGULATORY AUTHORITY OF PAKISTAN
DIVISION OF QUALITY ASSURANCE & LABORATORY TESTING

MEDICAL PRODUCT ALERT

DRAP ALERT NO. Nº II/S/11-26-54

Drug products declared Substandard by Drug Testing laboratories Punjab

Date: 16th November, 2026

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

Drug Testing Laboratories (DTL) of Punjab Province informed that the samples of below mentioned drug products have been declared as '***Substandard***'.

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	Telosin Capsule SR 0.4mg (Tamsulosin Hydrochloride sustained release pellets eq. to Tamsulosin 0.4mg)	57026	Briell Pharmaceuticals (Pvt.) Ltd., 538-C Sunder Industrial Estate Lahore	Drug testing Laboratory (DTL) Punjab, Multan has declared the samples of Telosin Capsule SR 0.4mg as "Substandard" on the basis of impurity testing.
2.	Bisgit 5mg tablet (Each film coated tablet contains: Bisoprolol Fumarate)	T12426	Glitz Pharma, plot No. 265, Industrial triangle Kahuta road, Islamabad	Drug Testing Laboratory (DTL) Punjab, Rawalpindi has declared the samples of Bisgit Tablet 5mg as "Substandard" on the basis of detection of some additional peaks in assay testing.

Risk Statement:

The use of the above-mentioned "Substandard" drug product may cause serious health consequences to patients since the effect of impurities and other substances present in the products, is unknown.

Action initiated: -

The Provincial Drug Control departments and DRAP's field offices have been asked to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

Advice for Pharmacies/Medical stores: -

All pharmacists and chemists working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the

supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above mentioned product are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using the drug products and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

Drug Regulatory Authority of Pakistan
محفوظ، موثر اور معیاری اشیائے